I think the percentage of that happening is 1% or less. Do you honestly think Elite would have invested all this time and money over all these years with phase 1/2, patents, Camargo, etc...if they did not in-house thoroughly test everything and know their tech works? A series of events, such as bad management and business model in the early years combined with the recession delayed their ART from coming to market. JT began the turn around with the generics and Naz is the closer with the pharma experience, knowledge and FDA insight. You can bet Naz has in-house tested and reviewed Elites ART thoroughly and knows it works "better then anything else out there" according to him. Elite is in the perfect storm right now with the FDA and congress mandating this tech. Good chance that Elite becomes the industry standard for all others to match or better IMO once the FDA gets done with the review.
This is correct. The subsequent ELI products will be taylored for their trials to meet the FDA criteria based on ELI200 approval so they can streamline the follow up products through the FDA process one after the other.
They have no losses unless they sell. Big question is why do you remain here 24/7 bashing a stock that you do not own?
Thanks for the chart posting. Agree technical indicators are pointing positive, accumulation continues, news will generate the volume and resistance will be futile.
Did I miss something here STOOPID? Did you finally identify yourself completely for the site in some fashion? Have you listed your multiple ID's under your true and correct name somewhere? IP addresses tell the story and LONGS know
Well now that is a more logical and reasonable way to view your "investment" not a one play gamble in Elite. Fundamentals are stronger then ever. Techinicals pointing positive. Patience critical.
Thank you and I also read all of your posts. Thank you for sharing your chart analysis expertise with us and explaining your opinions with attached charts. It is a difficult thing to master due to the MM manipulation that occurs daily with Elite but someday soon it will be much more difficult for them to manipulate the stock.
as compared to 2009? They have continued to improve year after year and that is a fact. Now they are on the cusp of their greatest achievement.
then perhaps you should leave now instead of sitting here each day whining and posting false info. Did not accomplish much in 2014? really do you want to see the extensive list of accomplishments for the year not to mention the over 100% increase in PPS for 2104? You are just another of those naive inexperienced investors who jumped onto the Elite train late during a little run up and thought you could make a million overnight and when you learn you cant do it and have to be patient then you whine and look for all sorts of excuses. Why don't you just sell and move on. It is that simple but why don't you do it. Why are you still here?
Again no intelligent response but then again none was anticipated either
Whoa tool boy,,,koolaid is wiping the floor again with you over on flub....you never learn do you tool boy?
as I figured, you have no factual response to my post about Camargo stats and how they relate to Elites NDA filing
For s small company that has turned itself completely around from a few years ago it certainly is GREAT financials. revenue increases quarter after quarter and year after year and now they have a new 6 million dollar generic in the pipeline as well. Step by step, no one will stop us
Pure factual info directly from their website so please dispute it if you think you can.
Factual statistics right from the Camargo website and since Elite is a client of theirs it directly relates to Elites upcoming NDA filing.
and you are here for 24/7 for what reason again tool boy?
All but one of the novel drugs approved to date in CY14 met their PDUFA goal dates for the approval review cycle
Almost three-quarters (74%) of the novel drugs approved to date in CY14 were approved in the first review cycle
More than half (57%) of the novel drugs approved to date in CY14 were approved under Priority Review
More than one-third (37%) of novel drugs approved to date in CY14 received Fast Track designation
Approximately four out of every ten (43%) novel drugs approved to date in CY14 were for rare diseases
Sentiment: Strong Buy